US labeling for Biogen Inc. and Alkermes PLC’s Vumerity (diroximel fumarate) does not address the gastrointestinal tolerability advantage over Biogen’s Tecfidera (dimethyl fumarate) that the companies have long said is the rationale for developing the new multiple sclerosis therapy.
The Food and Drug Administration granted full approval to the Vumerity NDA on 29 October 2019, shortly after issuing a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?